Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications.
J Neuroimmune Pharmacol
; 16(4): 718-721, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1469760
ABSTRACT
COVID-19 epidemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Several effective vaccines have been developed and extensive efforts are underway to develop therapeutics to treat COVID-19. Cannabis and/or its product-cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental/neurological complications and substance use disorders. However, research reviewed shows that there is insufficient data from clinical studies to support the use of cannabis or CBD for the treatment of COVID-19 associated mental health and neurological complications. Additional basic and clinical research is suggested to develop cannabis or cannabidiol for the treatment of mental health problems associated with coronavirus infection and or substance use disorders. In the meantime, it is important that the addiction physician/psychiatrist must caution while prescribing or recommending cannabis or CBD for treating such clinical indications. Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cannabidiol
/
Cannabinoids
/
Cannabis
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
J Neuroimmune Pharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
/
Neurology
Year:
2021
Document Type:
Article
Affiliation country:
S11481-021-10013-8
Similar
MEDLINE
...
LILACS
LIS